Please check your internet connection and try again.
# Amoxicillin-Clavulanate (Augmentin)
## Overview
Amoxicillin-clavulanate combines a penicillin antibiotic (amoxicillin) with a beta-lactamase inhibitor (clavulanate potassium). The addition of clavulanate expands the spectrum to include beta-lactamase-producing organisms.
## Primary Indications
* Acute bacterial rhinosinusitis
* Community-acquired pneumonia
* Skin and skin structure infections
* Animal/human bites
* Acute otitis media (AOM)
* Urinary tract infections
## Adult Dosing
* **Standard dosing:** 500 mg every 8 hours or 875 mg every 12 hours.
* **High-intensity dosing:** 2000 mg (extended-release formulation) every 12 hours for resistant *S. pneumoniae*.
* **Duration:** Typically 5–10 days depending on the infection site.
## Pediatric Dosing
* **General infection:** 25–45 mg/kg/day (based on amoxicillin component) divided every 12 hours.
* **Acute Otitis Media:** 80–90 mg/kg/day divided every 12 hours (using 7:1 or 14:1 suspension ratios to minimize clavulanate exposure).
* **Maximum:** Follow pediatric weight-based limits; do not exceed adult maximum strengths.
## Dose Adjustments
* **Renal Impairment (CrCl <30 mL/min):** Extended-release formulations and 875 mg tablets are contraindicated. Dose adjustments are required based on CrCl; consult renal dosing guidelines.
* **Hepatic Impairment:** Use with caution; monitor liver function.
## Contraindications
* History of amoxicillin-clavulanate-associated cholestatic jaundice or hepatic dysfunction.
* Severe penicillin allergy (hypersensitivity).
* Phenylketonuria (as some chewable/powder formulations contain aspartame).
## Adverse Effects
* **Gastrointestinal:** Diarrhea (most common, often exacerbated by clavulanate), nausea, vomiting.
* **Hepatic:** Asymptomatic elevation of transaminases (AST/ALT).
* **Dermatologic:** Rash (maculopapular), Stevens-Johnson syndrome (rare).
* **Other:** *Clostridioides difficile*-associated diarrhea, candidiasis.
## Key Drug Interactions
* **Methotrexate:** Amoxicillin may reduce renal clearance, increasing methotrexate toxicity.
* **Warfarin:** May increase INR/bleeding risk due to alteration of gut flora and vitamin K synthesis.
* **Probenecid:** Decreases renal tubular secretion of amoxicillin, increasing serum levels.
* **Oral Contraceptives:** Potential for decreased efficacy (controversial, but backup methods may be advised).
## Monitoring
* Monitor for signs of anaphylaxis or severe cutaneous adverse reactions (SCAR).
* Assess LFTs if therapy duration exceeds 14 days or if patient reports jaundice/dark urine.
* Monitor bowel habits for *C. difficile* symptoms (profuse diarrhea).
## Clinical Pearls
* **Administration:** Take with food or a meal to decrease gastrointestinal side effects.
* **Formulation Ratios:** Not all tablets are interchangeable. A 250 mg tablet and a 250 mg chewable tablet may contain different ratios of clavulanate and possess different dosing profiles.
* **Clavulanate-related GI Distress:** If diarrhea is dose-limiting, consider switching to a formulation with a lower clavulanate-to-amoxicillin ratio.
* **Guideline Dependency:** Dosing for AOM or sinusitis should strictly follow local guidelines (e.g., IDSA/AAP) to ensure appropriate coverage for resistant pathogens.
***
**Educational Disclaimer:** This information is for educational purposes and reflects standard clinical practice. Prescribing information, local resistance patterns, and institutional protocols must be verified against current drug labels (e.g., DailyMed) and clinical pharmacy resources prior to administration.
